Stock Option Plans (Tables)

12 Months Ended

Dec. 31, 2016

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

The following table summarizes consolidated stock-based compensation expense, including equity awards by privately-held consolidated subsidiaries, related to stock options and other equity awards for the years ended December 31, 2016, 2015, and 2014, which was allocated as follows (in thousands):

	Year Ended December 31,
	2016		2015		2014
Research and Development	$	2,608	$	3,267	$	1,310
General and Administrative		5,343		7,783		3,145
Total stock-based compensation expense	$	7,951	$	11,050	$	4,455

Schedule of weighted average assumptions to calculate fair value of stock options

The weighted-average estimated fair value of stock options granted under BioTime’s 2002 Plan and 2012 Plan during the years ended December 31, 2016, 2015 and 2014 was $1.69, $2.13 and $2.78 per share respectively, using the Black-Scholes Merton model with the following weighted-average assumptions:

	Year Ended December 31,
	2016		2015		2014
Expected life (in years)		5.83		5.62		6.67
Risk-free interest rates		1.45%		1.70%		2.19%
Volatility		61.24%		65.82%		83.20%
Dividend yield		0.00%		0.00%		0.00%

Additional information regarding options outstanding

Additional information regarding options outstanding under BioTime’s 2002 Plan and 2012 Plan as of December 31, 2016 is as follows (in thousands except exercise prices and weighted average exercise price):

				Options Outstanding					Options Exercisable

Range of Exercise Prices		Number Outstanding		Weighted Avg. Remaining Contractual Life (years)		Weighted Avg. Exercise Price			Number Exercisable		Weighted Avg. Exercise Price
	2.52-3.96		5,349		7.21		$	3.32		2,080		$	3.46
	4.02-4.95		1,429		3.80		$	4.25		1,225		$	4.26
	5.02-8.58		180		0.84		$	6.94		179		$	6.95
$	2.52-8.58		6,958		6.34		$	3.60		3,484		$	3.92

2002 Plan and 2012 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of share-based compensation, employee stock purchase plan, activity

A summary of all equity award activity under BioTime’s 2002 Plan and 2012 Plan for the years ended December 31, 2016, 2015 and 2014 is as follows (in thousands except weighted average exercise price):

	Shares Available for Grant			Number of Options Outstanding			Number of RSUs Outstanding		Weighted Average Exercise Price
January 1, 2014		2,315			4,567			-	$	2.71
Granted under 2012 Plan		(2,170	)		2,170			-		3.54
Exercised		-			(2,060	)		-		0.58
Forfeited/cancelled/expired under 2002 Plan		-			(179	)		-		4.32
Forfeited/cancelled/expired under 2012 Plan		523			(524	)		-		3.72
December 31, 2014		668			3,974			-	$	4.04
Increase in option pool		6,000			-					-
Granted under 2012 Plan		(1,650	)		1,650			-		3.72
Exercised		-			(156	)		-		4.00
Forfeited/cancelled/expired under 2002 Plan		-			(35	)		-		6.72
Forfeited/cancelled/expired under 2012 Plan		239			(239	)		-		3.82
December 31, 2015		5,257			5,194			-	$	3.93
Granted under 2012 Plan		(2,315	)		2,315			-		3.03
RSUs		(200	)		-			100		-
Common stock issued to consultant in lieu of cash		(28	)		-			-		-
Common stock issued to employee for bonuses in lieu of cash		(135	)		-			-		-
Forfeited/cancelled/expired under 2002 Plan		-			(236	)		-		5.17
Forfeited/cancelled/expired under 2012 Plan		315			(315	)		-		3.77
December 31, 2016		2,894			6,958			100	$	3.60

OncoCyte Common Stock Option Plans [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of share-based compensation, employee stock purchase plan, activity

A summary of OncoCyte’s Stock Option Plan activity follows (in thousands except weighted average exercise price):

	Shares Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
January 1, 2014		1,250			2,750		$	0.76
Options forfeited/cancelled		28			(28	)		1.00
December 31, 2014		1,278			2,722		$	0.76
Increase in option pool		4,000			-			-
Options granted		(2,875	)		2,875			1.10
Options exercised		-			(6	)		0.67
Options forfeited/cancelled		1,121			(1,121	)		0.79
2 for 1 reverse stock split		(1,762	)		(2,235	)		2.02
Options granted after reverse stock split		(10	)		10			3.60
Options forfeited/cancelled after reverse stock split		5			(5	)		2.00
December 31, 2015		1,757			2,240		$	2.94
Options granted		(962	)		962			3.58
Options exercised		-			(100	)		2.19
Options forfeited/cancelled		35			(35	)		2.03
Options expired		50			(50	)		2.00
December 31, 2016		880			3,017		$	2.52

A summary of OrthoCyte’s Stock Option Plan activity follows (in thousands except weighted average exercise price):

	Shares Available for Grant		Number of Options Outstanding			Weighted Average Exercise Price
December 31, 2014⁽¹⁾		1,355		2,645		$	0.08
Options forfeited/cancelled		16		(16	)		0.07
December 31, 2015		1,371		2,629		$	0.08
Options forfeited/cancelled		1,329		(1,329	)		0.10
December 31, 2016		2,700		1,300		$	0.06

(1) There was no grant activity during 2014.

ReCyte Therapeutics, Inc. [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of share-based compensation, employee stock purchase plan, activity

A summary of ReCyte’s Stock Option Plan activity follows (in thousands except weighted average exercise price):

	Shares Available for Grant		Number of Options Outstanding			Weighted Average Exercise Price
December 31, 2014⁽¹⁾		2,710		1,290		$	2.05
Options forfeited/cancelled		11		(11	)		2.05
December 31, 2015		2,721		1,279		$	2.05
Options forfeited/cancelled		29		(29	)		2.05
December 31, 2016		2,750		1,250		$	2.05

(1) There was no grant activity during 2014.

LifeMap Sciences, Inc. [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of share-based compensation, employee stock purchase plan, activity

A summary of LifeMap Sciences’ Equity Incentive Plan activity follows (in thousands except weighted average exercise price):

	Shares Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
January 1, 2014		413			1,929		$	1.49
Options forfeited/cancelled		58			(58	)		1.48
December 31, 2014		471			1,871		$	1.48
Options granted		(131	)		131			1.92
Options forfeited/cancelled		207			(207	)		1.79
December 31, 2015		547			1,795		$	1.47
Options granted		(20	)		20			2.25
Options forfeited/cancelled		219			(219	)		1.72
December 31, 2016		746			1,596		$	1.44

LifeMap Solutions, Inc [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of share-based compensation, employee stock purchase plan, activity

A summary of LifeMap Solutions’ Equity Incentive Plan activity follows (in thousands except weighted average exercise price):

	Options Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
Option pool added upon incorporation		19			-		$	0.00
Options granted		(13	)		13			500.00
December 31, 2014		6			13		$	500.00
Options granted		(2	)		2			500.00
Options forfeited/cancelled		1			(1	)		500.00
December 31, 2015		5			14		$	500.00
Options granted		(2	)		2			500.00
Options forfeited/cancelled		4			(4	)		500.00
December 31, 2016		7			12		$	500.00

Cell Cures Employee Share Ownership and Option Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of share-based compensation, employee stock purchase plan, activity

A summary of Cell Cure’s 2007 Employee Share Ownership and Option Plan and 2016 Share Option Plan activity follows (in thousands except weighted average exercise price):

	Options Available for Grant			Number of Options Outstanding		Weighted Average Exercise Price⁽²⁾
December 31, 2015⁽¹⁾		2			12	$	23.93
Increase to option under 2016 Share Option Plan		111			-		-
Options granted		(69	)		69		40.00
December 31, 2016		44			81	$	38.00

(1)

There was no grant activity during 2014 and 2015.

(2)

Cell Cure Neurosciences Share Option Plan US dollar exercise price shown is approximated based on the conversion rate between the US dollar and the New Israeli Shekel, NIS, at the time of grant. The exercise price is denominated in NIS.